Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Nephrology · LMX1B-Associated Nephropathy

The View Under the Microscope: Biopsy and Biology

At a Glance

An LMX1B nephropathy biopsy may look normal early or show FSGS on light microscopy. Electron microscopy can reveal an irregular, moth-eaten GBM and type III collagen, while immunofluorescence is usually negative; these clues support but do not replace genetic testing.

When a doctor performs a kidney biopsy, they are looking for the microscopic “fingerprints” of a disease. In isolated LMX1B-associated nephropathy, these prints can be very subtle and require careful interpretation alongside genetic results [1][2].

A Simplified Biological Mechanism

To understand the biopsy, you first have to understand the LMX1B gene’s job. In the kidney, this gene acts as a transcriptional regulator for podocytes—the sophisticated cells that wrap around your kidney’s tiny blood filters (glomeruli) to prevent protein from leaking into your urine [3][4].

When the LMX1B gene is mutated, the gene program for the podocyte is disrupted, affecting proteins such as NPHS1 (which makes nephrin) and WT1 [4][5]. Without these proteins, the podocytes cannot maintain the filter properly. The blueprint for the filter’s foundation, the Glomerular Basement Membrane (GBM), also becomes flawed [2][6].

What the Biopsy Shows

A kidney biopsy is examined in three different ways. In LMX1B-associated disease, each “view” provides supportive clues.

1. Light Microscopy (The Wide View)

This view often shows generic patterns of damage [1].

  • Minimal Change: In the early stages, the kidney may look almost normal [1][7].
  • FSGS: As the disease progresses, it often shows a pattern of Focal Segmental Glomerulosclerosis (FSGS)—a pattern of scarring that looks similar to immune-mediated FSGS [1][6].

2. Immunofluorescence (The “Glow” Test)

This test looks for antibodies or immune deposits. In this condition, the test is usually negative or shows nonspecific staining [8]. Positive or “pauci-immune” results require specialist interpretation and could indicate a coexisting condition [8].

3. Electron Microscopy (The Deep View)

This is where supportive specific clues may be found. Pathologists look for:

  • Moth-Eaten Appearance: The GBM may look irregular, with clear spots that resemble a moth-eaten sweater [1][6].
  • Type III Collagen: Finding bundles of type III collagen inside the filter wall is a strong supportive clue for an LMX1B mutation [2][9].
  • Foot-Process Effacement: The “feet” of the podocytes appear flattened, which is common in many proteinuric diseases [10][1].

These findings are supportive; they are not required, and their absence does not exclude a genetically confirmed diagnosis.

Potential Diagnostic Mimics

The biopsy can sometimes provide differential clues:

  • Fabry Disease or Medications: Sometimes, pathologists see small structures called myelin figures or zebra bodies [6][11]. These can appear in Fabry disease, from certain medications, or in LMX1B-associated nephropathy [11][12].
  • Alport Syndrome: Because both conditions affect the collagen in the kidney filter, the thinning or fraying of the filter wall can sometimes look like Alport Syndrome [13][14].

Pathology Report Checklist

When reviewing your biopsy report, you can ask your renal pathologist about:

  1. Light Microscopy (LM): Did it show patterns like “Minimal Change” or “FSGS”?
  2. Immunofluorescence (IF): Was it negative, or did it show immune deposits?
  3. Electron Microscopy (EM): Did it evaluate the GBM for thickness and any supportive clues like collagen fibrils and foot-process effacement? [1][2]

Common questions in this guide

What changes might appear on a kidney biopsy with LMX1B nephropathy?
An early biopsy may look nearly normal or show minimal change. As the disease progresses, light microscopy may show focal segmental glomerulosclerosis, or FSGS, while electron microscopy may reveal an irregular glomerular basement membrane, type III collagen bundles, or podocyte foot-process effacement. These findings support the diagnosis but are not required for it.
Does negative immunofluorescence rule out LMX1B-associated nephropathy?
No. Immunofluorescence is often negative or shows nonspecific staining in LMX1B-associated nephropathy, so the diagnosis depends on the complete clinical, genetic, and biopsy picture. Immune deposits or a positive result may suggest a coexisting condition and should be reviewed by a specialist.
What does type III collagen in the glomerular basement membrane mean?
Bundles of type III collagen within the glomerular basement membrane can support an LMX1B mutation as the cause of kidney disease. This finding should be interpreted together with genetic results and the other biopsy findings rather than used alone to make a diagnosis.
Can zebra bodies on a kidney biopsy have causes other than LMX1B nephropathy?
Yes. Myelin figures or zebra bodies can occur in LMX1B-associated nephropathy, Fabry disease, or after exposure to certain medicines such as chloroquine or amiodarone. Your clinician may review your medication history and consider testing for Fabry disease.
Does the absence of a moth-eaten glomerular basement membrane rule out LMX1B nephropathy?
No. A moth-eaten or irregular glomerular basement membrane on electron microscopy is a supportive clue, not a required finding. Its absence does not exclude LMX1B-associated nephropathy when genetic and clinical evidence support the diagnosis.
How do minimal change disease and FSGS fit into an LMX1B biopsy report?
Minimal change may be seen early, while FSGS is a pattern of scarring that may appear as the disease progresses. These are patterns seen under light microscopy and do not, by themselves, establish LMX1B-associated nephropathy.

Get notified when new evidence is published on Nail-patella-like renal disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Clinical and histological findings of autosomal dominant renal-limited disease with LMX1B mutation.

    Konomoto T, Imamura H, Orita M, et al.

    Nephrology (Carlton, Vic.) 2016; (21(9)):765-73 doi:10.1111/nep.12666.

    PMID: 26560070
  2. 2

    LMX1B-Associated Nephropathy With Type III Collagen Deposition in the Glomerular and Tubular Basement Membranes.

    Andeen NK, Schleit J, Blosser CD, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; (72(2)):296-301 doi:10.1053/j.ajkd.2017.09.023.

    PMID: 29246420
  3. 3

    Spectrum of LMX1B mutations: from nail-patella syndrome to isolated nephropathy.

    Harita Y, Kitanaka S, Isojima T, et al.

    Pediatric nephrology (Berlin, Germany) 2017; (32(10)):1845-1850 doi:10.1007/s00467-016-3462-x.

    PMID: 27450397
  4. 4

    Dysregulation of WTI (-KTS) is Associated with the Kidney-Specific Effects of the LMX1B R246Q Mutation.

    Hall G, Lane B, Chryst-Ladd M, et al.

    Scientific reports 2017; (7()):39933 doi:10.1038/srep39933.

    PMID: 28059119
  5. 5

    Nail-patella syndrome.

    Witzgall R

    Pflugers Archiv : European journal of physiology 2017; (469(7-8)):927-936 doi:10.1007/s00424-017-2013-z.

    PMID: 28681095
  6. 6

    LMX1B-associated nephropathy that showed myelin figures on electron microscopy.

    Shimohata H, Miyake Y, Yoshida Y, et al.

    CEN case reports 2021; (10(4)):588-591 doi:10.1007/s13730-021-00612-y.

    PMID: 34076843
  7. 7

    Focal segmental glomerulosclerosis associated with undescribed mutation in the LMX1B gene.

    Martín Gómez MA, Caba Molina M, León Fradejas M, et al.

    European journal of medical genetics 2024; (72()):104980 doi:10.1016/j.ejmg.2024.104980.

    PMID: 39490407
  8. 8

    Case report: dual pathology of LMX1B-associated nephropathy and iga nephropathy in a middle-aged woman.

    Sajjad A, Amer R, Alsayed M, et al.

    BMC nephrology 2026; (27(1)).

    PMID: 41992156
  9. 9

    Collagenofibrotic Glomerulopathy.

    Miyake M, Katayama K, Ehara T, et al.

    Internal medicine (Tokyo, Japan) 2021; (60(6)):911-915 doi:10.2169/internalmedicine.6090-20.

    PMID: 33055489
  10. 10

    Clinicopathological characteristics and cyclosporine-responsive proteinuria in nail-patella syndrome with a novel LMX1B mutation.

    Jiang L, Feng S, Xu Z, et al.

    Pediatric nephrology (Berlin, Germany) 2026; (41(4)):1013-1024 doi:10.1007/s00467-025-07036-1.

    PMID: 41249554
  11. 11

    Myelin bodies in LMX1B-associated nephropathy: potential for misdiagnosis.

    Lei L, Oh G, Sutherland S, et al.

    Pediatric nephrology (Berlin, Germany) 2020; (35(9)):1647-1657 doi:10.1007/s00467-020-04564-w.

    PMID: 32356190
  12. 12

    Nail-patella-like renal disease masquerading as Fabry disease on kidney biopsy: a case report.

    Pinto E Vairo F, Pichurin PN, Fervenza FC, et al.

    BMC nephrology 2020; (21(1)):341 doi:10.1186/s12882-020-02012-3.

    PMID: 32791958
  13. 13

    A case of concurrent Alport syndrome and Nail-patella syndrome posing diagnostic challenge without genetic testing.

    Fung WW, Yau ML, Lam PPH, et al.

    BMC nephrology 2025; (26(1)):668 doi:10.1186/s12882-025-04606-1.

    PMID: 41299396
  14. 14

    A Novel Mutation in LMX1B (p.Pro219Ala) Causes Focal Segmental Glomerulosclerosis with Alport Syndrome-like Phenotype.

    Oe Y, Mishima E, Mori T, et al.

    Internal medicine (Tokyo, Japan) 2021; (60(18)):2991-2996 doi:10.2169/internalmedicine.6987-20.

    PMID: 33814499

This page explains how biopsy findings may support an LMX1B-associated nephropathy diagnosis, but it cannot interpret your individual report. Discuss your results with a nephrologist or renal pathologist; this information is educational and does not constitute medical advice.